CN102666550B - 作为orl-1受体拮抗剂的螺环哌啶化合物 - Google Patents

作为orl-1受体拮抗剂的螺环哌啶化合物 Download PDF

Info

Publication number
CN102666550B
CN102666550B CN201080051845.3A CN201080051845A CN102666550B CN 102666550 B CN102666550 B CN 102666550B CN 201080051845 A CN201080051845 A CN 201080051845A CN 102666550 B CN102666550 B CN 102666550B
Authority
CN
China
Prior art keywords
methyl
pyran
mmol
fluoro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080051845.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102666550A (zh
Inventor
A·B·贝尼托克拉多
N·迪亚兹比佐
A·M·吉梅尼兹-阿瓜多
C·拉富恩特布兰科
M·A·马蒂内兹-格劳
C·佩德雷加尔-特塞罗
M·A·托莱多埃斯克里巴诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102666550A publication Critical patent/CN102666550A/zh
Application granted granted Critical
Publication of CN102666550B publication Critical patent/CN102666550B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080051845.3A 2009-11-16 2010-11-12 作为orl-1受体拮抗剂的螺环哌啶化合物 Expired - Fee Related CN102666550B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382245.0 2009-11-16
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
US61/298,628 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (2)

Publication Number Publication Date
CN102666550A CN102666550A (zh) 2012-09-12
CN102666550B true CN102666550B (zh) 2015-07-15

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080051845.3A Expired - Fee Related CN102666550B (zh) 2009-11-16 2010-11-12 作为orl-1受体拮抗剂的螺环哌啶化合物

Country Status (18)

Country Link
US (1) US20120214784A1 (cg-RX-API-DMAC7.html)
EP (1) EP2501704B1 (cg-RX-API-DMAC7.html)
JP (1) JP5723381B2 (cg-RX-API-DMAC7.html)
KR (1) KR101368130B1 (cg-RX-API-DMAC7.html)
CN (1) CN102666550B (cg-RX-API-DMAC7.html)
AU (1) AU2010319400B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011710A2 (cg-RX-API-DMAC7.html)
CA (1) CA2781041C (cg-RX-API-DMAC7.html)
DK (1) DK2501704T3 (cg-RX-API-DMAC7.html)
EA (1) EA020391B1 (cg-RX-API-DMAC7.html)
ES (1) ES2436241T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130969T1 (cg-RX-API-DMAC7.html)
MX (1) MX2012005690A (cg-RX-API-DMAC7.html)
PL (1) PL2501704T3 (cg-RX-API-DMAC7.html)
PT (1) PT2501704E (cg-RX-API-DMAC7.html)
RS (1) RS53017B (cg-RX-API-DMAC7.html)
SI (1) SI2501704T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011060217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3497101B1 (de) 2016-08-10 2020-12-30 Bayer CropScience Aktiengesellschaft Substituierte 2-heterocyclyl-imidazolyl-carboxamide als schädlingsbekämpfungsmittel
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005066183A1 (de) * 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor
CN101227903A (zh) * 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005066183A1 (de) * 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor
CN1922189A (zh) * 2003-12-23 2007-02-28 格吕伦塔尔有限公司 对orl1受体具有亲合力的螺环环己烷衍生物
CN101227903A (zh) * 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design, synthesis, and structure–activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine;Takashi Yoshizumi,等;《Bioorganic & Medicinal Chemistry Letters》;20080516;第18卷(第13期);第3778-3782页,参见全文 *

Also Published As

Publication number Publication date
WO2011060217A1 (en) 2011-05-19
JP5723381B2 (ja) 2015-05-27
EA201290355A1 (ru) 2012-10-30
EP2501704A1 (en) 2012-09-26
BR112012011710A2 (pt) 2016-03-01
PT2501704E (pt) 2013-12-05
US20120214784A1 (en) 2012-08-23
JP2013510870A (ja) 2013-03-28
MX2012005690A (es) 2012-06-13
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
EP2501704B1 (en) 2013-09-18
AU2010319400B2 (en) 2013-12-19
EA020391B1 (ru) 2014-10-30
ES2436241T3 (es) 2013-12-27
DK2501704T3 (da) 2013-10-14
CN102666550A (zh) 2012-09-12
CA2781041A1 (en) 2011-05-19
SI2501704T1 (sl) 2013-11-29
PL2501704T3 (pl) 2014-02-28
RS53017B (sr) 2014-04-30
HRP20130969T1 (hr) 2013-11-22
KR20120082927A (ko) 2012-07-24
AU2010319400A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CN102666550A (zh) 作为orl-1受体拮抗剂的螺环哌啶化合物
CN102612520B (zh) 作为orl-1受体拮抗剂的螺哌啶化合物
CN109526220A (zh) 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂*和四氢吡啶并二氮杂*化合物
JP2009528318A (ja) シグマ受容体化合物
US20240417407A1 (en) Furoindazole derivatives as gpr84 antagonists
KR20180073638A (ko) 통증에 대해 활성을 갖는 옥사-디아자스피로 화합물들
HK1169988B (en) Spiropiperidine compounds as orl-1 receptor antagonists
TW200524608A (en) Therapeutic agents
BR112012012150A2 (pt) compostos spiro piperidina como antagonistas de recep-tor orl-1
CN101528750B (zh) 作为选择性酸泵抑制剂的苯并咪唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150715

Termination date: 20201112

CF01 Termination of patent right due to non-payment of annual fee